A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures
- Healthy male and female subjects aged 18 to 50 years with veins suitable for cannulation or repeated venepuncture; female subjects must be postmenopausal or surgically sterile. Female subjects must have a negative pregnancy test at screening and on admi
- Male subjects should be willing to use barrier contraception ie, condoms, from dosing to 3 months after dosing with the IP (investigational product).
- Have a body mass index (BMI) between 19 and 30 kg/m2
- As judged by the Investigator, all the subjects must be able to understand and be willing to comply with study procedures, restrictions and requirements
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
- History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to avibactam, ceftazidime, and/or excipients
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP Prolonged QTcF (>450 ms) or shortened QTcF (<350 ms) or a family history of long QT syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
CAZ104 (2000mg Ceftazidime/500mg Avibactam)
|
IV infusion
|
|
ACTIVE_COMPARATOR: 2
500mg Avibactam
|
IV infusion
|
|
ACTIVE_COMPARATOR: 3
2000mg Ceftazidime
|
IV infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including maximum plasma concentration (Cmax)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Cmax (tmax)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including minimum plasma concentration (Cmin)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Cmin (tmin)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including last quantifiable plasma concentration (Clast)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including time of Clast (tlast)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including average plasma concentration during a dosing interval (Cavg)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including fluctuation index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including area under the curve of plasma drug concentration (AUC) - time curve from zero to the time of the last quantifiable concentration
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including AUC, Day 1 only
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including AUC during the dosing interval [AUC(0-τ)]
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including terminal half-life (t1/2)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including systemic plasma clearance (CL)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including volume of distribution at steady state (Vss)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including volume of distribution at the terminal phase (Vz)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including accumulation ratio for Cmax and AUC(0-τ)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Plasma pharmacokinetic variables will be measured including linearity index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including amount of drug excreted unchanged into urine from zero to time t [Ae(0-t)]
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including fraction of dose excreted unchanged into urine (fe; % dose)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Avibactam. Urine pharmacokinetic variables will be measured including renal clearance (CLR)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cmax
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tmax
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cmin
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tmin
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Clast
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including tlast
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Cavg
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including fluctuation index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC(0-t)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC, Day 1 only
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including AUC(0-τ)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including t1/2
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including CL
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Vss
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including Vz
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including accumulation ratio for Cmax and AUC(0-τ)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Plasma pharmacokinetic variables will be measured including linearity index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including Ae(0-t)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including fe; % dose
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part A: Single- and multiple-dose pharmacokinetics of Ceftazidime. Urine pharmacokinetic variables will be measured including CLR
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Cmax
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including tmax
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Cmin
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including tmin
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Clast
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including tlast
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Cavg
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including fluctuation index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including AUC(0-t)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including AUC, Day 1 only
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including AUC(0-τ)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including t1/2
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including CL
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Vss
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including Vz
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including accumulation ratio for Cmax and AUC(0-τ)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Plasma pharmacokinetic variables will be measured including linearity index
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Urine pharmacokinetic variables will be measured including Ae(0-t)
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Urine pharmacokinetic variables will be measured including fe; % dose
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
Part B: Pharmacokinetics of co-administering Avibactam plus Ceftazidime (CAZ104) compared to administration of the individual components. Urine pharmacokinetic variables will be measured including CLR
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess safety and tolerability of Avibactam by assessment of Adverse events
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Avibactam by clinical laboratory assessments
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Avibactam by assessment of vital signs
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Avibactam by assessment of safety electrocardiogram
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Avibactam by assessment of physical examination
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Avibactam by assessment of withdrawn
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by assessment of Adverse events
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by clinical laboratory assessments
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by assessment of vital signs
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by assessment of safety electrocardiogram
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by assessment of physical examination
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of Ceftazidime by assessment of withdrawn
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by assessment of Adverse events
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by clinical laboratory assessments
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by assessment of vital signs
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by assessment of safety electrocardiogram
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by assessment of physical examination
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
|
To assess safety and tolerability of CAZ104 by assessment of withdrawn
Time Frame: Up to 24 hours post last dose
|
Up to 24 hours post last dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Mirjana Kujacic, MD, AstraZeneca Research and DevelopmentSE-431 83 Mölndal Sweden
- Principal Investigator: Leonard Siew, MBCHB, Quintiles Drug Research Unit at Guy's Hospital 6 Newcomen St London SE1 1YR United Kingdom
- Study Director: Paul Newell, MD, AstraZeneca R&D Alderly Park, Mereside SK 104 TG Macclesfield, Cheshire United Kingdom
Publications and helpful links
General Publications
- Das S, Li J, Armstrong J, Learoyd M, Edeki T. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015 Oct;3(5):e00172. doi: 10.1002/prp2.172. Epub 2015 Aug 25.
- Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG, Riccobene T, Carrothers TJ, Das S. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clin Transl Sci. 2019 Mar;12(2):151-163. doi: 10.1111/cts.12585. Epub 2018 Sep 28.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D4280C00011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.